FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2746014535> ?p ?o ?g. }

• W2746014535 endingPage "98" @default.
• W2746014535 startingPage "88" @default.
• W2746014535 abstract "Lebrikizumab is a humanized monoclonal antibody that binds to interleukin-13 and has been evaluated as a treatment for moderate-to-severe asthma. Objectives of this work were to characterize lebrikizumab pharmacokinetics (PK), identify influential covariates, and graphically explore exposure-response relationships in moderate-to-severe asthmatics. Pooled PK data from 11 studies were used in the population PK model development. Full covariate modeling was used to evaluate the impact of pre-specified covariates. Response data (exacerbation rate, forced expiratory volume in 1 s [FEV1], and fractional exhaled nitric oxide [FeNO]) were obtained from moderate-to-severe asthmatics (n = 2148) who received placebo, lebrikizumab 37.5 mg or 125 mg every 4 weeks (Q4W) in two replicate phase 3 studies. Graphical exposure-response analyses were stratified by numerous covariates, including biomarker subgroups defined by serum periostin level and blood eosinophil count at baseline. Lebrikizumab PK was described by a two-compartment model with first-order absorption. Population typical values were estimated as 0.156 L/day for clearance (CL), 4.10 L for central volume (Vc), and 0.239 day−1 for absorption rate (ka), 85.6% for bioavailability (inter-subject variability: CL, 33.3%; Vc, 36.3%; ka, 40.8%). The estimated mean terminal half-life was 25.7 days. Body weight was the most influential covariate. Generally, the exposure-response analyses of FEV1 and FeNO showed increased response at higher exposure quartiles, while flat or unclear exposure-response relationships were observed in exacerbation rate. Lebrikizumab PK is as expected for a typical immunoglobulin G4 monoclonal antibody. Results from the exposure-response analyses suggested that, compared to 125 mg Q4W, the 37.5 mg Q4W dose did not achieve the maximum responses for FEV1 and FeNO, although it appeared to maximize the effect on exacerbation reduction. This suggests that the antibody levels needed to improve these outcomes may not be the same. In addition, the role of IL-13 in airflow obstruction/airway inflammation and asthma exacerbations might be different and targeting multiple pathways may be required to treat this heterogeneous disease and provide clinically meaningful benefits to asthma patients." @default.
• W2746014535 created "2017-08-31" @default.
• W2746014535 creator A5002962155 @default.
• W2746014535 creator A5016643106 @default.
• W2746014535 creator A5018805442 @default.
• W2746014535 creator A5031467011 @default.
• W2746014535 creator A5062001477 @default.
• W2746014535 creator A5065578593 @default.
• W2746014535 creator A5072337935 @default.
• W2746014535 creator A5075602404 @default.
• W2746014535 creator A5088297113 @default.
• W2746014535 creator A5090566767 @default.
• W2746014535 date "2017-10-01" @default.
• W2746014535 modified "2023-10-14" @default.
• W2746014535 title "Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma" @default.
• W2746014535 cites W1506450640 @default.
• W2746014535 cites W1955799244 @default.
• W2746014535 cites W1992025888 @default.
• W2746014535 cites W2046313062 @default.
• W2746014535 cites W2046974419 @default.
• W2746014535 cites W2063049671 @default.
• W2746014535 cites W2067933166 @default.
• W2746014535 cites W2098276532 @default.
• W2746014535 cites W2116916381 @default.
• W2746014535 cites W2120416054 @default.
• W2746014535 cites W2127482775 @default.
• W2746014535 cites W2128472414 @default.
• W2746014535 cites W2132665714 @default.
• W2746014535 cites W2153395214 @default.
• W2746014535 cites W2161446377 @default.
• W2746014535 cites W2342693354 @default.
• W2746014535 cites W2370552689 @default.
• W2746014535 cites W2515900781 @default.
• W2746014535 cites W2589241064 @default.
• W2746014535 cites W4240211429 @default.
• W2746014535 doi "https://doi.org/10.1016/j.pupt.2017.08.010" @default.
• W2746014535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28843617" @default.
• W2746014535 hasPublicationYear "2017" @default.
• W2746014535 type Work @default.
• W2746014535 sameAs 2746014535 @default.
• W2746014535 citedByCount "13" @default.
• W2746014535 countsByYear W27460145352017 @default.
• W2746014535 countsByYear W27460145352019 @default.
• W2746014535 countsByYear W27460145352020 @default.
• W2746014535 countsByYear W27460145352021 @default.
• W2746014535 countsByYear W27460145352022 @default.
• W2746014535 countsByYear W27460145352023 @default.
• W2746014535 crossrefType "journal-article" @default.
• W2746014535 hasAuthorship W2746014535A5002962155 @default.
• W2746014535 hasAuthorship W2746014535A5016643106 @default.
• W2746014535 hasAuthorship W2746014535A5018805442 @default.
• W2746014535 hasAuthorship W2746014535A5031467011 @default.
• W2746014535 hasAuthorship W2746014535A5062001477 @default.
• W2746014535 hasAuthorship W2746014535A5065578593 @default.
• W2746014535 hasAuthorship W2746014535A5072337935 @default.
• W2746014535 hasAuthorship W2746014535A5075602404 @default.
• W2746014535 hasAuthorship W2746014535A5088297113 @default.
• W2746014535 hasAuthorship W2746014535A5090566767 @default.
• W2746014535 hasBestOaLocation W27460145351 @default.
• W2746014535 hasConcept C105795698 @default.
• W2746014535 hasConcept C112705442 @default.
• W2746014535 hasConcept C119043178 @default.
• W2746014535 hasConcept C126322002 @default.
• W2746014535 hasConcept C139254425 @default.
• W2746014535 hasConcept C185592680 @default.
• W2746014535 hasConcept C189165786 @default.
• W2746014535 hasConcept C203014093 @default.
• W2746014535 hasConcept C2776042228 @default.
• W2746014535 hasConcept C2777014857 @default.
• W2746014535 hasConcept C2777699602 @default.
• W2746014535 hasConcept C2780333948 @default.
• W2746014535 hasConcept C2781142857 @default.
• W2746014535 hasConcept C2781197716 @default.
• W2746014535 hasConcept C2908647359 @default.
• W2746014535 hasConcept C33923547 @default.
• W2746014535 hasConcept C44249647 @default.
• W2746014535 hasConcept C55493867 @default.
• W2746014535 hasConcept C68443243 @default.
• W2746014535 hasConcept C71924100 @default.
• W2746014535 hasConcept C86803240 @default.
• W2746014535 hasConcept C95444343 @default.
• W2746014535 hasConcept C99454951 @default.
• W2746014535 hasConceptScore W2746014535C105795698 @default.
• W2746014535 hasConceptScore W2746014535C112705442 @default.
• W2746014535 hasConceptScore W2746014535C119043178 @default.
• W2746014535 hasConceptScore W2746014535C126322002 @default.
• W2746014535 hasConceptScore W2746014535C139254425 @default.
• W2746014535 hasConceptScore W2746014535C185592680 @default.
• W2746014535 hasConceptScore W2746014535C189165786 @default.
• W2746014535 hasConceptScore W2746014535C203014093 @default.
• W2746014535 hasConceptScore W2746014535C2776042228 @default.
• W2746014535 hasConceptScore W2746014535C2777014857 @default.
• W2746014535 hasConceptScore W2746014535C2777699602 @default.
• W2746014535 hasConceptScore W2746014535C2780333948 @default.
• W2746014535 hasConceptScore W2746014535C2781142857 @default.
• W2746014535 hasConceptScore W2746014535C2781197716 @default.
• W2746014535 hasConceptScore W2746014535C2908647359 @default.
• W2746014535 hasConceptScore W2746014535C33923547 @default.

• next